Cover Image
Market Research Report

Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Published by Prescient & Strategic Intelligence Private Limited Product code 862054
Published Content info 187 Pages
Delivery time: 2-3 business days
Price
Back to Top
Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024
Published: April 19, 2019 Content info: 187 Pages
Description

The biosimilars market is predicted to reach $26.7 billion by 2024, progressing at a CAGR of 29.6% during the forecast period (2019-2024), according to P&S Intelligence. The market is driven by the rising prevalence of chronic disease, growing investment in research and development by biopharmaceutical organizations, vast pipeline of biosimilars, surging geriatric population, and the cost-efficient nature of biosimilars as compared to approved drugs.

Based on technology, the biosimilars market is classified into monoclonal antibody (mAb), bioassays, nuclear magnetic resonance (NMR), recombinant deoxyribonucleic acid (rDNA), and electrophoresis. Biosimilars manufactured using the mAb technology held 56.0% share in the market in 2018. This technology is further anticipated to be the fastest growing due to its large-scale deployment in the development of therapeutics to treat various diseases, such as immunological, cancer, and infections.

On a global ground, in 2018, Europe dominated the biosimilars market with nearly 47.7% share. This is ascribed to the flexible regulatory parameters, surging aging population, and increasing R&D investments by biopharmaceutical organizations in the region.

The biosimilars market is expected to observe the fastest growth in North America, progressing at CAGR of 32.7% during the 2019-2024 period. This can be mainly attributed to the surging geriatric population, increasing prevalence of chronic diseases, and growth in R&D investments.

Companies in North America have more freedom to price their products as they want compared to other regions, and advanced technologies and trained scientific personnel are readily available in here, which make it ideal for pharmaceutical companies.

According to the Population Reference Bureau report, titled Aging in the United States, the aging population is anticipated to double by 2060, resulting in the need for old age-related disease management. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 60.0% of the adults in the U.S. are suffering from one or more chronic diseases.

Strategic collaborations and product launches play a prominent role in the growth of the biosimilars market. For instance, Amgen Inc. and Entera Bio Ltd. collaborated in 2018 to launch an orally administered formulation of biologics. This collaboration shows that organizations are ready to invest in biologics, resulting in the growth of the market.

Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the business of biosimilars in China. With the collaboration, Samsung Bioepis Co. Ltd. will seek to enlarge its biosimilars portfolio, while 3SBio Group will be supported by the sales of Avastin.

Some of the key players operating in the market, globally, are Samsung Bioepis Co. Ltd., AMEGA Biotech, Synthon Holding B.V., Coherus BioSciences Inc., Celltrion Inc., BIOCAD, Zydus Cadila, Teva Pharmaceutical Industries Limited, Pfizer Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., and Mylan N.V.

Global Biosimilars Market Segmentation

Market Segmentation by Product

  • Recombinant Glycosylated Proteins
    • Monoclonal antibodies (mAbs)
    • Erythropoietin
    • Follitropin
  • Recombinant Non-Glycosylated Proteins
    • Insulin
    • Recombinant human growth hormone
    • Granulocyte-colony stimulating factor (G-CSF)
    • Interferons
  • Recombinant Peptides

Market Segmentation by Technology

  • Monoclonal Antibody (mAb)
  • Recombinant Deoxyribonucleic Acid (rDNA)
  • Bioassays
  • Nuclear Magnetic Resonance (NMR)
  • Electrophoresis

Market Segmentation by Indication

  • Oncology
  • Rheumatology
  • Blood-Related Disorders
  • Auto-Immune Diseases
  • Chronic Diseases
  • Infectious Diseases
  • Growth Hormone Deficiency (GHD)
  • Others

Market Segmentation by Manufacturing Type

  • Contract
  • In-House

Market Segmentation by Route of Administration (ROA)

  • Intravenous
  • Subcutaneous
  • Intranasal
  • Others

Market Segmentation by Geography

  • Europe Biosimilars Market
    • By product
    • By technology
    • By indication
    • By manufacturing type
    • By ROA
    • By country - Germany, France, U.K., Italy, Spain, Sweden, Russia, Switzerland, Austria, Netherlands, Belgium, Norway, and Rest of Europe
  • Asia-Pacific (APAC) Biosimilars Market
    • By product
    • By technology
    • By indication
    • By manufacturing type
    • By ROA
    • By country - China, Japan, India, South Korea, Singapore, Australia, Thailand, Indonesia, Malaysia, and Rest of APAC
  • North America Biosimilars Market
    • By product
    • By technology
    • By indication
    • By manufacturing type
    • By ROA
    • By country - U.S. and Canada
  • Latin America (LATAM) Biosimilars Market
    • By product
    • By technology
    • By indication
    • By manufacturing type
    • By ROA
    • By country - Brazil, Mexico, Argentina, Columbia, and Rest of LATAM
  • Middle East & Africa (MEA) Biosimilars Market
    • By product
    • By technology
    • By indication
    • By manufacturing type
    • By ROA
    • By country - U.A.E., Israel, South Africa, Saudi Arabia, and Rest of MEA
Table of Contents

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Product
    • 1.3.2 Market Segmentation by Technology
    • 1.3.3 Market Segmentation by Indication
    • 1.3.4 Market Segmentation by Manufacturing Type
    • 1.3.5 Market Segmentation by Route of Administration (ROA)
    • 1.3.6 Market Segmentation by Geography
    • 1.3.7 Analysis Period
    • 1.3.8 Market Data Reporting Unit
      • 1.3.8.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Product
      • 4.1.1.1 Recombinant glycosylated proteins
        • 4.1.1.1.1 mAbs
        • 4.1.1.1.2 Erythropoietin
        • 4.1.1.1.3 Follitropin
      • 4.1.1.2 Recombinant non-glycosylated proteins
        • 4.1.1.2.1 Insulin
        • 4.1.1.2.2 Recombinant human growth hormone
        • 4.1.1.2.3 G-CSF
        • 4.1.1.2.4 Interferons
      • 4.1.1.3 Recombinant peptides
    • 4.1.2 By Technology
      • 4.1.2.1 mAb
      • 4.1.2.2 rDNA
      • 4.1.2.3 Bioassays
      • 4.1.2.4 NMR
      • 4.1.2.5 Electrophoresis
    • 4.1.3 By Indication
      • 4.1.3.1 Oncology
      • 4.1.3.2 Rheumatology
      • 4.1.3.3 Blood-related disorders
      • 4.1.3.4 Auto-immune diseases
      • 4.1.3.5 Chronic diseases
      • 4.1.3.6 Infectious diseases
      • 4.1.3.7 GHD
      • 4.1.3.8 Others
    • 4.1.4 By Manufacturing Type
      • 4.1.4.1 Contract
      • 4.1.4.2 In-house
    • 4.1.5 By ROA
      • 4.1.5.1 Intravenous
      • 4.1.5.2 Subcutaneous
      • 4.1.5.3 Intranasal
      • 4.1.5.4 Others
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Increasing number of collaborations and partnerships
      • 4.2.1.2 Rapid product launches
    • 4.2.2 Drivers
      • 4.2.2.1 Growing geriatric population
      • 4.2.2.2 Increasing prevalence of chronic diseases
      • 4.2.2.3 Increasing R&D investment by biopharmaceutical companies and extensive pipeline of biosimilars
      • 4.2.2.4 Inexpensive nature of biosimilar drugs
      • 4.2.2.5 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 Complex manufacturing process
      • 4.2.3.2 Strict regulations and delays in approvals
  • 4.3 Porter's Five Forces Analysis
  • 4.4 Pricing Policies for Biosimilars
  • 4.5 Pricing Scenario for Biosimilars
  • 4.6 Positive Attributes for Biosimilar Pricing

Chapter 5. Global Market Size and Forecast

  • 5.1 By Product
    • 5.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 5.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 5.2 By Technology
  • 5.3 By Indication
  • 5.4 By Manufacturing Type
  • 5.5 By ROA
  • 5.6 By Region

Chapter 6. Europe Market Size and Forecast

  • 6.1 By Product
    • 6.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 6.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 6.2 By Technology
  • 6.3 By Indication
  • 6.4 By Manufacturing Type
  • 6.5 By ROA
  • 6.6 By Country

Chapter 7. APAC Market Size and Forecast

  • 7.1 By Product
    • 7.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 7.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 7.2 By Technology
  • 7.3 By Indication
  • 7.4 By Manufacturing Type
  • 7.5 By ROA
  • 7.6 By Country

Chapter 8. North America Market Size and Forecast

  • 8.1 By Product
    • 8.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 8.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 8.2 By Technology
  • 8.3 By Indication
  • 8.4 By Manufacturing Type
  • 8.5 By ROA
  • 8.6 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Product
    • 9.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 9.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 9.2 By Technology
  • 9.3 By Indication
  • 9.4 By Manufacturing Type
  • 9.5 By ROA
  • 9.6 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Product
    • 10.1.1 Recombinant Glycosylated Proteins Market, by Type
    • 10.1.2 Recombinant Non-Glycosylated Proteins Market, by Type
  • 10.2 By Technology
  • 10.3 By Indication
  • 10.4 By Manufacturing Type
  • 10.5 By ROA
  • 10.6 By Country

Chapter 11. Competitive Landscape

  • 11.1 Benchmarking of Key Players Based on Indication
  • 11.2 Global Strategic Development of Key Players
    • 11.2.1 Product Launches
    • 11.2.2 Geographic Expansions

Chapter 12. Company Profiles

  • 12.1 AMEGA Biotech
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
  • 12.2 Samsung Bioepis Co. Ltd.
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
  • 12.3 Coherus BioSciences Inc.
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 Synthon Holding B.V.
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
  • 12.5 BIOCAD
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
      • 12.5.2.1 Marketed products
      • 12.5.2.2 Pipeline products
  • 12.6 Zydus Cadila
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
    • 12.6.3 Key Financial Summary
  • 12.7 Celltrion Inc.
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
      • 12.7.2.1 Marketed products
      • 12.7.2.2 Pipeline products
    • 12.7.3 Key Financial Summary
  • 12.8 Dr. Reddy's Laboratories Ltd.
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
    • 12.8.3 Key Financial Summary
  • 12.9 Teva Pharmaceutical Industries Limited
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Novartis AG
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
      • 12.10.2.1 Marketed products
      • 12.10.2.2 Pipeline products
    • 12.10.3 Key Financial Summary
  • 12.11 Pfizer Inc.
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
      • 12.11.2.1 Marketed products
      • 12.11.2.2 Pipeline products
    • 12.11.3 Key Financial Summary
  • 12.12 Mylan N.V.
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

List of Tables

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 PRICE COMPARISON BETWEEN BIOSIMILARSS AND BIOLOGICS
  • TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 5 PRICE OF KEY BIOSIMILARS
  • TABLE 6 BIOSIMILARS ADAPTABILITY- COUNTRY-WISE ANALYSIS
  • TABLE 7 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 8 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 9 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 10 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 11 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 12 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 13 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 14 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 15 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 16 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 17 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 18 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 19 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 20 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 21 GLOBAL BIOSIMILARS MARKET, BY REGION, $M (2014-2018)
  • TABLE 22 GLOBAL BIOSIMILARS MARKET, BY REGION, $M (2019-2024)
  • TABLE 23 EUROPEAN MEDICINES AGENCY (EMA) APPROVED BIOSIMILARS
  • TABLE 24 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 25 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 26 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 27 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 28 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 29 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 30 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 31 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 32 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 33 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 34 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 35 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 36 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 37 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 38 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 39 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 40 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 41 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 42 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 43 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 44 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 45 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 46 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 47 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 48 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 49 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 50 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 51 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 52 APAC BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 53 APAC BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 54 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 55 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 56 EXPIRATION YEAR OF SOME BIOLOGIC PATENTS IN THE U.S.
  • TABLE 57 BIOSIMILARS APPROVED IN CANADA
  • TABLE 58 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 59 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 60 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 61 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 62 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 63 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 64 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 65 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 66 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 67 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 68 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 69 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 70 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 71 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 72 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 73 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 74 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 75 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 76 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 77 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 78 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 79 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 80 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 81 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 82 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 83 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 84 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 85 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 86 LATAM BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 87 LATAM BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 88 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 89 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 90 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 91 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 92 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 93 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 94 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2018)
  • TABLE 95 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019-2024)
  • TABLE 96 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2018)
  • TABLE 97 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019-2024)
  • TABLE 98 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2014-2018)
  • TABLE 99 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2019-2024)
  • TABLE 100 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2018)
  • TABLE 101 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019-2024)
  • TABLE 102 MEA BIOSIMILARS MARKET, BY ROA, $M (2014-2018)
  • TABLE 103 MEA BIOSIMILARS MARKET, BY ROA, $M (2019-2024)
  • TABLE 104 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 105 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 106 AMEGA BIOTECH - AT A GLANCE
  • TABLE 107 SAMSUNG BIOEPIS CO. LTD. - AT A GLANCE
  • TABLE 108 APPROVED PRODUCTS OF SAMSUNG BIOEPIS CO. LTD.
  • TABLE 109 PIPELINE PRODUCTS OF SAMSUNG BIOEPIS CO. LTD.
  • TABLE 110 COHERUS BIOSCIENCES INC. - AT A GLANCE
  • TABLE 111 COHERUS BIOSCIENCES INC. - KEY FINANCIAL SUMMARY
  • TABLE 112 SYNTHON HOLDING B.V. - AT A GLANCE
  • TABLE 113 BIOPHARMACEUTICALS OFFERED BY SYNTHON HOLDING B.V.
  • TABLE 114 BIOCAD - AT A GLANCE
  • TABLE 115 ZYDUS CADILA - AT A GLANCE
  • TABLE 116 ZYDUS CADILA - KEY FINANCIAL SUMMARY
  • TABLE 117 CELLTRION INC. - AT A GLANCE
  • TABLE 118 BIOSMILARS PIPELINE PRODUCTS OF CELLTRION INC.
  • TABLE 119 BIOLOGICS PIPELINE PRODUCTS OF CELLTRION INC.
  • TABLE 120 CELLTRION INC. - KEY FINANCIAL SUMMARY
  • TABLE 121 DR. REDDY'S LABORATORIES LTD. - AT A GLANCE
  • TABLE 122 DR. REDDY'S LABORATORIES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 123 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - AT A GLANCE
  • TABLE 124 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 125 NOVARTIS AG - AT A GLANCE
  • TABLE 126 NOVARTIS AG - KEY FINANCIAL SUMMARY
  • TABLE 127 PFIZER INC. - AT A GLANCE
  • TABLE 128 PFIZER INC. - KEY FINANCIAL SUMMARY
  • TABLE 129 MYLAN N.V. - AT A GLANCE
  • TABLE 130 MYLAN N.V. - KEY FINANCIAL SUMMARY

List of Figures

  • FIG 1 RESEARCH METHODOLOGY
  • FIG 2 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 6 DATA TRIANGULATION APPROACH
  • FIG 7 GLOBAL BIOSIMILARS MARKET SUMMARY
  • FIG 8 BARGAINING POWER OF BUYERS
  • FIG 9 BARGAINING POWER OF SUPPLIERS
  • FIG 10 INTENSITY OF RIVALRY
  • FIG 11 THREAT OF NEW ENTRANTS
  • FIG 12 THREAT OF SUBSTITUTES
  • FIG 13 POSITIVE ATTRIBUTES FOR BIOSIMILAR PRICING
  • FIG 14 GLOBAL BIOSIMILARS MARKET SNAPSHOT (2018)
  • FIG 15 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 16 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 17 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 18 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 19 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 20 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 21 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 22 WORLDWIDE MAJOR MARKETS FOR BIOSIMILARS
  • FIG 23 EUROPE BIOSIMILARS MARKET SNAPSHOT
  • FIG 24 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 25 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 26 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 27 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 28 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 29 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 30 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 31 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 32 APAC BIOSIMILARS MARKET SNAPSHOT
  • FIG 33 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 34 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 35 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 36 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 37 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 38 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 39 APAC BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 40 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 41 NORTH AMERICA BIOSIMILARS MARKET SNAPSHOT
  • FIG 42 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 43 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 44 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 45 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 46 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 47 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 48 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 49 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 50 LATAM BIOSIMILRS MARKET SNAPSHOT
  • FIG 51 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 52 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 53 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 54 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 55 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 56 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 57 LATAM BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 58 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 59 MEA BIOSIMILARS MARKET SNAPSHOT
  • FIG 60 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 61 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 62 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014-2024)
  • FIG 63 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014-2024)
  • FIG 64 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2014-2024)
  • FIG 65 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014-2024)
  • FIG 66 MEA BIOSIMILARS MARKET, BY ROA, $M (2014-2024)
  • FIG 67 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 68 BENCHMARKING OF KEY PLAYERS
  • FIG 69 ZYDUS CADILA - REVENUE SPLIT BY GEOGRAPHY (2018)
  • FIG 70 CELLTRION INC. - REVENUE SPLIT BY SEGMENT (2017)
  • FIG 71 DR. REDDY'S LABORATORIES LTD. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2018)
  • FIG 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2018)
  • FIG 73 NOVARTIS AG - REVENUE SPLIT BY MARKETED PRODUCTS AND GEOGRAPHY (2018)
  • FIG 74 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2018)
  • FIG 75 MYLAN N.V. - REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2018)
Back to Top